385 related articles for article (PubMed ID: 27973629)
1. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks.
Zhang RX; Ahmed T; Li LY; Li J; Abbasi AZ; Wu XY
Nanoscale; 2017 Jan; 9(4):1334-1355. PubMed ID: 27973629
[TBL] [Abstract][Full Text] [Related]
2. An update on strategies for optimizing polymer-lipid hybrid nanoparticle-mediated drug delivery: exploiting transformability and bioactivity of PLN and harnessing intracellular lipid transport mechanism.
Ahmed T; Liu FF; Wu XY
Expert Opin Drug Deliv; 2024 Feb; 21(2):245-278. PubMed ID: 38344771
[TBL] [Abstract][Full Text] [Related]
3. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN).
Li Y; Taulier N; Rauth AM; Wu XY
Pharm Res; 2006 Aug; 23(8):1877-87. PubMed ID: 16850265
[TBL] [Abstract][Full Text] [Related]
4. Lipid-coated polymeric nanoparticles for cancer drug delivery.
Krishnamurthy S; Vaiyapuri R; Zhang L; Chan JM
Biomater Sci; 2015 Jul; 3(7):923-36. PubMed ID: 26221931
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
Wong HL; Bendayan R; Rauth AM; Wu XY
J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
[TBL] [Abstract][Full Text] [Related]
6. Exploitation of lipid-polymeric matrices at nanoscale for drug delivery applications.
Sgorla D; Bunhak ÉJ; Cavalcanti OA; Fonte P; Sarmento B
Expert Opin Drug Deliv; 2016 Sep; 13(9):1301-9. PubMed ID: 27110648
[TBL] [Abstract][Full Text] [Related]
7. Lipid polymer hybrid as emerging tool in nanocarriers for oral drug delivery.
Hallan SS; Kaur P; Kaur V; Mishra N; Vaidya B
Artif Cells Nanomed Biotechnol; 2016; 44(1):334-49. PubMed ID: 25237838
[TBL] [Abstract][Full Text] [Related]
8. Exploring the transformability of polymer-lipid hybrid nanoparticles and nanomaterial-biology interplay to facilitate tumor penetration, cellular uptake and intracellular targeting of anticancer drugs.
Amini MA; Ahmed T; Liu FF; Abbasi AZ; Soeandy CD; Zhang RX; Prashad P; Cummins CL; Rauth AM; Henderson JT; Wu XY
Expert Opin Drug Deliv; 2021 Jul; 18(7):991-1004. PubMed ID: 33703991
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
10. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.
Li Y; Abbaspour MR; Grootendorst PV; Rauth AM; Wu XY
Eur J Pharm Biopharm; 2015 Aug; 94():170-9. PubMed ID: 25986587
[TBL] [Abstract][Full Text] [Related]
11. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
12. Core-shell-type lipid-polymer hybrid nanoparticles as a drug delivery platform.
Mandal B; Bhattacharjee H; Mittal N; Sah H; Balabathula P; Thoma LA; Wood GC
Nanomedicine; 2013 May; 9(4):474-91. PubMed ID: 23261500
[TBL] [Abstract][Full Text] [Related]
13. Polymeric Lipid Hybrid Nanoparticles: Properties and Therapeutic Applications.
Jose C; Amra K; Bhavsar C; Momin M; Omri A
Crit Rev Ther Drug Carrier Syst; 2018; 35(6):555-588. PubMed ID: 30317969
[TBL] [Abstract][Full Text] [Related]
14. Novel surface modified polymer-lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation.
Pardeshi CV; Belgamwar VS; Tekade AR; Surana SJ
J Mater Sci Mater Med; 2013 Sep; 24(9):2101-15. PubMed ID: 23728521
[TBL] [Abstract][Full Text] [Related]
15. Polymer-Lipid Hybrid Nanoparticles: A Next-Generation Nanocarrier for Targeted Treatment of Solid Tumors.
Rizwanullah M; Alam M; Harshita ; Mir SR; Rizvi MMA; Amin S
Curr Pharm Des; 2020; 26(11):1206-1215. PubMed ID: 31951163
[TBL] [Abstract][Full Text] [Related]
16. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and
Surve DH; Jirwankar YB; Dighe VD; Jindal AB
Mol Pharm; 2020 Oct; 17(10):3990-4003. PubMed ID: 32808785
[TBL] [Abstract][Full Text] [Related]
18. Lipid-Polymer Hybrid Nanoparticles Synthesized via Lipid-Based Surface Engineering for a robust drug delivery platform.
Soomherun N; Kreua-Ongarjnukool N; Niyomthai ST; Chumnanvej S
Colloids Surf B Biointerfaces; 2024 May; 237():113858. PubMed ID: 38547797
[TBL] [Abstract][Full Text] [Related]
19. Polymer-lipid hybrid systems: merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery.
Rao S; Prestidge CA
Expert Opin Drug Deliv; 2016; 13(5):691-707. PubMed ID: 26866382
[TBL] [Abstract][Full Text] [Related]
20. Engineering of a hybrid polymer-lipid nanocarrier for the nasal delivery of tenofovir disoproxil fumarate: physicochemical, molecular, microstructural, and stability evaluation.
Pokharkar VB; Jolly MR; Kumbhar DD
Eur J Pharm Sci; 2015 Apr; 71():99-111. PubMed ID: 25708940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
